Stoke Therapeutics, Inc. Board of Directors

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Ms. Shamim Ruff M.S.

Ms. Shamim Ruff M.S.

Senior VP of Quality & Chief Regulatory Affairs Officer

Mr. Thomas Edward Leggett

Mr. Thomas Edward Leggett

Chief Financial Officer

Ms. Isabel Aznarez Ph.D.

Ms. Isabel Aznarez Ph.D.

Co-Founder, Head of Research & Senior VP

Mr. Jonathan Allan J.D.

Mr. Jonathan Allan J.D.

Corporate Secretary & General Counsel

Ms. Dawn Kalmar

Ms. Dawn Kalmar

Chief Communications Officer

Dr. Adrian R. Krainer Ph.D.

Dr. Adrian R. Krainer Ph.D.

Co-Founder & Independent Director

Mr. Eric Rojas

Mr. Eric Rojas

Head of Investor Relations

Ms. Joan Wood

Ms. Joan Wood

Chief Human Resources Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.